P. Cherin

Hôpitaux Universitaires La Pitié salpêtrière - Charles Foix, Lutetia Parisorum, Île-de-France, France

Are you P. Cherin?

Claim your profile

Publications (235)469.08 Total impact

  • La Revue de Médecine Interne 06/2014; 35:A155-A156. DOI:10.1016/j.revmed.2014.03.257 · 1.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To assess the outcome of interstitial lung disease (ILD) in anti-Jo-1 patients with antisynthetase syndrome, determine predictive variables of ILD deterioration in these patients, and compare features of anti-Jo-1 patients with and without ILD.Methods Ninety-one anti-Jo-1 patients were identified by medical records search in 4 medical centers. All of these patients had undergone pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) scans.ResultsSixty-six patients (72.5%) had ILD. Patients could be divided into 3 groups according to their presenting lung manifestations: acute onset of lung disease (n = 12), progressive onset of lung signs (n = 35), and asymptomatic patients exhibiting abnormalities consistent with ILD on PFTs and HRCT scans (n = 19). Sixteen patients had resolution of ILD; 39 and 11 patients experienced improvement and deterioration of ILD, respectively. ILD led to decreased functional status, since 29.8% of patients exhibited a marked reduction of activities due to ILD and 13.6% had respiratory insufficiency requiring oxygen therapy; 5 of 6 patients died due to ILD complications. Predictive parameters of ILD deterioration were HRCT scan pattern of usual interstitial pneumonia, respiratory muscle involvement, and age ≥55 years. Furthermore, anti-Jo-1 patients with ILD, compared with those without, more frequently exhibited mechanic's hands and lower creatine kinase levels.Conclusion Our findings confirm that ILD is a frequent complication in anti-Jo-1 patients, resulting in high morbidity. We suggest that patients with predictive factors of ILD deterioration may require more aggressive therapy. Finally, anti-Jo-1 patients with ILD, compared with those without, may exhibit a particular clinical phenotype.
    05/2013; 65(5). DOI:10.1002/acr.21895
  • P. Cherin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Myopathies in the elderly are relatively frequent and regularly underestimated. The clinical manifestations suggestive of a myopathy are somewhat unspecific: myalgia, weakness, fatigue or intolerance during effort and the problem is linking them to ageing. Certain genetic myopathies only appear in adulthood, sometimes after the fifth decade. But the great majority of myopathies in the elderly are of acquired origin: dysimmune (notably inclusion body myositis), endocrine (thyroiditis) and above all toxic or iatrogenic first of all due to two myotoxic drugs: corticoids and hypercholesterol lowering drugs (mainly statins). It is necessary, when confronted with any persistent myalgia or muscular fatigability, to request muscular enzymes and an electromyography before referring the patient to a specialized department.
    NPG Neurologie - Psychiatrie - Gériatrie 01/2013; 14(79). DOI:10.1016/j.npg.2013.06.006
  • P. Cherin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Dietary excess of saturated fats and cholesterol accounts for the most common cause of moderate LDL-C elevation, a major and independent predictor of cardiovascular disease-related morbidity and mortality. Among various treatments including diet and pharmacologic therapy affecting various pathways of cholesterol absorption and metabolism, statins are the currently available and most powerful LDL-C lowering agents leading to an effective cardiovascular mortality and morbidity decrease. Statins use is safe but muscular intolerance, a common related-disorder, is a difficult challenge to manage.
    NPG Neurologie - Psychiatrie - Gériatrie 01/2013; 14(79). DOI:10.1016/j.npg.2013.06.005

  • La Revue de Médecine Interne 12/2012; 33:A194-A195. DOI:10.1016/j.revmed.2012.10.354 · 1.07 Impact Factor

  • La Revue de Médecine Interne 12/2012; 33:A194. DOI:10.1016/j.revmed.2012.10.353 · 1.07 Impact Factor
  • P. Cherin · E. Voronska · N. Fraoucene · C. de Jaeger ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Pesticides constitute a very heterogeneous group of chemical substances adapted to the wrestling against plants and unwanted animals: weed-killers, fungicides, insecticides, acaricides, nématicides and rodenticides mainly. These phytosanitary products possess all a toxicity, of variable intensity, for the human. The acute toxicity of pesticides results from a misuse, from an accidental use of pesticides (accidents in the home) or from an often very serious voluntary poisoning. Organophosphate pesticides and carbamates are at the origin of the cases of poisonings by the most frequent pesticides. The exposure is essentially made by cutaneo-mucous and respiratory way, oral exposure would concern more the general population by accidental or deliberate ingestion of pesticides. According to the World Health Organization (WHO), there is every year in the world one million grave poisonings by pesticides, at the origin of approximately 220,000 deaths a year.
    Medecine et Longevite 06/2012; 4(2):68–74. DOI:10.1016/j.mlong.2012.05.003

  • La Revue de Médecine Interne 06/2012; 33:S40-S41. DOI:10.1016/j.revmed.2012.03.013 · 1.07 Impact Factor
  • C. de Jaeger · P. Cherin · N. Fraoucene · E. Voronska ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The problems of environment became a major concern of our societies, in particular the risk bound to the exposure in pesticides. France remains a big consumer of pesticides: third world user and first consumer in Europe. These pesticides are used in 90% by the agriculture. The presence and the obstinacy of these phytosanitary products (and or of their residues) in our grounds, groundwaters, food cycle, and finally for a certain number, in our plates, worry a big part of the scientific community. And the proofs of their harmfulness for the human health, difficult to bring to light because of the complexity of the problem, begin to accumulate.
    Medecine et Longevite 06/2012; 4(2):59–67. DOI:10.1016/j.mlong.2012.05.004
  • C. de Jaeger · E. Voronska · N. Fraoucene · P. Cherin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The risks for the health of pesticides are the object of numerous debates. If the data remain controversial at the adult with the exception of lymphomas, associations are found more frequently in the cancers of the child, in particular brain tumours, leukaemia and nephroblatomes. In brain tumours, an association is frequently evoked during a professional exhibition (exposure) of the relatives (parents) at the time of the pregnancy. Diverse consequences of pesticides on the reproduction were evoked: infertility, fœtal death, prematurity, hypotrophia, congenital malformations; but the studies suffer certain ways. Pesticides can interfere with hormones (endocrine disruptors), growth factors or neurotransmitters. The study of the neurological appearances in connection with the use of pesticides seems to be established. In particular, the link between the use of pesticides and the arisen of a Parkinson's disease appears at present as likely, in view of the numerous realized works.
    Medecine et Longevite 06/2012; 4(2):75–92. DOI:10.1016/j.mlong.2012.05.002
  • C. de Jaeger · P. Cherin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Within the vascular wall, endothelial cells, vascular smooth muscle cells and fibroblasts are surrounded by a complex and structured network of secreted macromolecules and proteins, the extracellular matrix. The extracellular matrix provides a structural framework essential for the functional properties of tissues. In each tissue, the three-dimensional organisation of the extracellular matrix molecules – elastin, collagens, proteoglycans and structural glycoproteins – synthesized during development and growth is optimal for these functions. Reciprocal interactions between matrix and cells are essential to growth, development and remodeling. In adult tissues, proteases are constitutively expressed but have a very low activity and the turnover of elastic and collagen fibers is very low. During ageing, the interaction of environmental factors (glucose, lipids, calcium…) and modifications of the biosynthesis and degradation processes lead to modifications of extracellular matrix homeostasis and consequently to alterations of tissue functionality. The extracellular matrix of old large elastic arteries undergoes several modifications. The elastic lamellae are fragmented or degraded and calcify, whereas more rigid proteins, such as collagen, accumulate and cause fibrosis. These alterations are associated with the stiffening of arteries, which results in the development of isolated systolic hypertension.
    Medecine et Longevite 03/2012; 4(1):41–53. DOI:10.1016/j.mlong.2012.02.002

  • La Revue de Médecine Interne 12/2011; 32:S259. DOI:10.1016/j.revmed.2011.10.291 · 1.07 Impact Factor

  • La Revue de Médecine Interne 12/2011; 32:S259. DOI:10.1016/j.revmed.2011.10.290 · 1.07 Impact Factor
  • C. de Jaeger · P. Cherin ·

    Medecine et Longevite 12/2011; 3(4). DOI:10.1016/j.mlong.2011.10.001
  • Source
    I Marie · PY Hatron · S Dominique · P Cherin · L Mouthon · J-F Menard ·
    [Show abstract] [Hide abstract]
    ABSTRACT: This study was undertaken to assess the characteristics and outcome of interstitial lung disease (ILD) in polymyositis/dermatomyositis (PM/DM) and to determine variables predictive of ILD deterioration in PM/DM. Among 348 consecutive patients with PM/DM, 107 patients with ILD were identified by medical records search in 4 medical centers. All patients underwent pulmonary function tests (PFTs) and pulmonary high-resolution computed tomography (HRCT) scan. ILD onset preceded PM/DM clinical manifestations in 20 patients, was identified concurrently with PM/DM in 69 patients, and occurred after PM/DM onset in 18 patients. Patients with ILD could be divided into 3 groups according to their presenting lung manifestations: patients with acute lung disease (n = 20), patients with progressive-course lung signs (n = 55), and asymptomatic patients with abnormalities consistent with ILD evident on PFTs and HRCT scan (n = 32). We observed that 32.7% of the patients had resolution of pulmonary disorders, whereas 15.9% experienced ILD deterioration. Factors that predicted a poor ILD prognosis were older age, symptomatic ILD, lower values of vital capacity and diffusing capacity for carbon monoxide, a pattern of usual interstitial pneumonia on HRCT scan and lung biopsy, and steroid-refractory ILD. The mortality rate was higher in patients with ILD deterioration than in those without ILD deterioration (47.1% versus 3.3%). Our findings indicate that ILD results in high morbidity in PM/DM. Our findings also suggest that more aggressive therapy may be required in PM/DM patients presenting with factors predictive of poor ILD outcome.
    Arthritis & Rheumatology 11/2011; 63(11):3439-47. DOI:10.1002/art.30513 · 7.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aims of this present study were to: 1) assess the characteristics of hematological malignancies in polymyositis/polymyositis (PM/DM) patients; and 2) determine predictive variables of hematological malignancies in PM/DM patients. We retrospectively reviewed the medical records of 32 patients (14 PM, 18 DM) associated with hematological malignancies. In our 32 PM/DM patients, hematological malignancy was concurrently identified (18.8%) or occurred during the course of PM/DM (31.2%); although, PM/DM more often preceded hematological malignancy onset (50%). We observed that the types of hematological malignancies varied, consisting of: B-cell lymphoma (n=20), T-cell lymphoma (n=4), Hodgkin's disease (n=2), multiple myeloma (n=1), myelodysplastic syndrome without excess of blasts (n=3), hairy cell (n=1) and acute lymphocytic leukemia (n=1). In 21 patients of our 32 patients with PM/DM-associated hematological malignancy (65.6% of cases), PM/DM paralleled the course of hematological malignancy. Finally, we observed that patients with PM/DM-associated hematological malignancies had a poor prognosis, the survival status ranging from 96.9%, 78.1% and 51.4% at 1, 3 and 5years, respectively. Interestingly, we found that patients with hematological malignancies, compared with those without were older and more frequently had DM; on the other hand, these patients less commonly exhibited: joint involvement (p=0.017), interstitial lung disease (p=0.06) and anti-Jo1 antibody (p=0.001). Taken together, our study underscores that the association between PM/DM and hematological malignancy, especially lymphoma, should not be ignored. Our findings also suggest that antisynthetase syndrome may be a protective factor of hematological malignancy in PM/DM patients.
    Autoimmunity reviews 10/2011; 11(9):615-20. DOI:10.1016/j.autrev.2011.10.024 · 7.93 Impact Factor
  • C. de Jaeger · P. Cherin ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The degenerative osteoarthritis is the most widespread and the most frequent articular disease of the chronic degenerative arthropathies. Osteoarthritis is a multifactorial disease, with a major genetic component, leading to the destruction of cartilage and joint dysfunction. The degenerative osteoarthritis is the resultant of the mechanical and biological phenomena which destabilize the balance between the synthesis and the degradation of the cartilage and which rings on all the articular and periarticular structures (synovial, liquid synovial, subchondral bone, capsule, ligaments). The numerous risk factors of degenerative osteoarthritis are henceforth better included, in particular the role of the excess weight, leptin and pro-inflammatory cytokines. Pro-inflammatory cytokines, particularly interleukin-1 and some enzymes including metalloproteases (MMP-13…) are involved in osteoarthritis process, cartilage destruction, deterioration of subchondral bone and synovial inflammation. The current treatment is based on the education of the patient, exercises, dietary measures, simple analgesic and nonsteroidal anti-inflammatory drugs, local treatments and viscosupplementation, disease-modifier drug for osteoarthritis and the surgery. The new treatments currently being studied include inflammation mechanism inhibitors, symptomatic slow acting drug for osteoarthritis and new disease-modifying osteoarthritis drugs.
    Medecine et Longevite 09/2011; 3(3):116-136. DOI:10.1016/j.mlong.2011.04.001
  • P. Cherin · C. de Jaeger ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Low back pain is one of the most frequent pathologies in industrial nations. Low back pain is considered to be chronic if it has been present for longer than 3 months. Low back pain constitutes the second cause of consultation and the third cause of request of incapacity. The treatment and the prevention of low back pain represent major stakes in public health. The chronic low back pain comes along with a physical deconditioning, and frequently with a progressive desocialisation. The chronic low back pain constitutes a multidimensional syndrome, containing a strong psychosocial constituent. So, numerous risk factors of passage in the chronicity were highlighted, whose most important are work and psychosocial factors. Treatment for chronic low back pain may last from a few weeks to several months, and usually takes a multimodality approach, in which several different therapies (drug, physical, interventional, complementary, psychological) are used in combination with one another. The indications of the surgery in chronic low back pain remain limited.
    Medecine et Longevite 09/2011; 3(3):137–149. DOI:10.1016/j.mlong.2011.08.002

  • La Revue de Médecine Interne 06/2011; 32. DOI:10.1016/j.revmed.2011.03.088 · 1.07 Impact Factor

  • La Revue de Médecine Interne 06/2011; 32. DOI:10.1016/j.revmed.2011.03.121 · 1.07 Impact Factor

Publication Stats

2k Citations
469.08 Total Impact Points


  • 2009-2013
    • Hôpitaux Universitaires La Pitié salpêtrière - Charles Foix
      Lutetia Parisorum, Île-de-France, France
  • 1992-2011
    • Hôpital La Pitié Salpêtrière (Groupe Hospitalier "La Pitié Salpêtrière - Charles Foix")
      • Service de Médecine Interne 1
      Lutetia Parisorum, Île-de-France, France
  • 2010
    • Hôpital Saint-Antoine (Hôpitaux Universitaires Est Parisien)
      • Service de Médecine Interne
      Paris, Ile-de-France, France
    • Centre Hospitalier Universitaire Rouen
      • Service d'Urologie
      Rouen, Haute-Normandie, France
  • 2001
    • CHU de Québec
      Quebec City, Quebec, Canada
    • Université Paris-Est Créteil Val de Marne - Université Paris 12
      Créteil, Île-de-France, France
  • 1991-1993
    • Hôpital Antoine-Béclère – Hôpitaux universitaires Paris-Sud
      Clamart, Île-de-France, France